Physician profile
Eric D Batts
NPI 1821126830
$9,034.10
in general payments reported to CMS, 2019-2025
60 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $20.59 · 2021: $35.85 · 2022: $1,268 · 2023: $2,296 · 2024: $2,035 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,986 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,985.86 |
| Education | $173.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,227.89 | 2019-2025 | Datroway, Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $681.88 | 2019-2025 | Truqap, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $592.15 | 2022-2025 | |
| Pfizer INC. | $421.83 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $419.93 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $406.80 | 2019-2025 | Tecentriq, Rozlytrek, Alecensa |
| Takeda Pharmaceuticals U.S.A., INC. | $404.61 | 2022-2025 | Fruzaqla, Iclusig |
| Eisai INC. | $376.37 | 2022-2025 | |
| Janssen Biotech, INC. | $269.59 | 2019-2025 | Talvey, Darzalex, Erleada |
| Astellas Pharma US INC | $269.41 | 2019-2025 | Xtandi, Cresemba, Xospata |
| Glaxosmithkline, LLC. | $233.53 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Pharmacyclics LLC, An Abbvie Company | $229.78 | 2022-2023 | Imbruvica |
| Gilead Sciences, INC. | $227.48 | 2021-2024 | Trodelvy |
| Abbvie INC. | $224.46 | 2022-2025 | Venclexta |
| Jazz Pharmaceuticals INC. | $172.06 | 2022-2025 | Zepzelca |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $165.50 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Celgene Corporation | $147.45 | 2022-2023 | Pomalyst, Reblozyl |
| Exelixis INC. | $145.71 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $119.88 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Foundation Medicine, INC. | $112.08 | 2019 | |
| Genzyme Corporation | $108.38 | 2022-2025 | |
| Tersera Therapeutics LLC | $108.17 | 2022-2025 | Xermelo, Zoladex |
| Array Biopharma INC | $104.67 | 2019-2024 | Mektovi, Braftovi, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $103.72 | 2023-2025 | Opdivo, Opdualag |
| Emd Serono, INC. | $100.47 | 2023-2025 | Bavencio, Tepmetko |
| Telix Pharmaceuticals | $100.00 | 2025 | Illuccix |
| Beigene USA, INC. | $97.52 | 2022-2024 | Brukinsa |
| Astrazeneca Uk Limited | $94.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $93.88 | 2024-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $78.03 | 2023-2025 | |
| Seagen INC. | $74.54 | 2022-2023 | Adcetris, Tukysa |
| Kyowa Kirin, INC. | $72.94 | 2022-2025 | Poteligeo |
| Mirati Therapeutics, INC. | $68.85 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $66.44 | 2022 | |
| Puma Biotechnology, INC. | $66.41 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $63.01 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $56.56 | 2022-2023 | Xpovio |
| Amgen INC. | $55.53 | 2019-2023 | Blincyto |
| Sumitomo Pharma America, INC. | $52.81 | 2023-2025 | Orgovyx |
| Progenics Pharmaceuticals, INC. | $50.75 | 2023 | Pylarify |
| Kite Pharma, INC. | $44.32 | 2025 | Yescarta |
| Taiho Oncology, INC. | $43.25 | 2022-2023 | |
| Adc Therapeutics America, INC. | $42.73 | 2024-2025 | |
| Stemline Therapeutics INC. | $42.71 | 2023-2024 | Elzonris |
| Rigel Pharmaceuticals, INC. | $39.50 | 2022 | |
| Agios Pharmaceuticals, INC. | $35.42 | 2025 | Pyrukynd |
| Springworks Therapeutics, INC. | $34.42 | 2024 | Ogsiveo |
| Sun Pharmaceutical Industries INC. | $29.93 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.73 | 2023 | Gilotrif |
| Amneal Pharmaceuticals LLC | $29.19 | 2025 | Alymsys |
| Geron Corporation | $27.20 | 2025 | Rytelo |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Beone Medicines USA, INC. | $23.81 | 2025 | Brukinsa |
| Sobi, INC | $22.77 | 2024 | |
| Pharmaessentia USA Corporation | $19.42 | 2024 | Besremi |
| Acrotech Biopharma INC. | $18.99 | 2022 | |
| Deciphera Pharmaceuticals INC. | $16.76 | 2023 | Qinlock |
| Aveo Pharmaceuticals, INC. | $15.48 | 2025 | |
| Caris Mpi, INC. | $15.11 | 2025 | Mi Cancer Seek |
| Cti Biopharma Corp. | $13.68 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Batts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.